The current BRNS market cap is 40.23M. The company's latest EPS is USD and P/E is N/A.
Year End December 30 2023 | 2021 | 2022 | 2023 |
---|---|---|---|
USD ($) | USD ($) | USD ($) | |
Total Revenue | 600k | 45.27M | 1.88M |
Operating Income | -40.89M | -2.58M | -79.37M |
Net Income | -50.87M | 5.34M | -73.35M |
Year End December 30 2023 | 2021 | 2022 | 2023 |
---|---|---|---|
USD ($) | USD ($) | USD ($) | |
Total Assets | 280.72M | 270.21M | 214.51M |
Total Liabilities | 28.15M | 27M | 27.51M |
Total Equity | 252.56M | 243.2M | 187M |
Market Cap | 40.23M |
Price to Earnings Ratio | N/A |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 0 |
Price to Book Ratio | 0 |
Dividend Yield | - |
Shares Outstanding | 40.23M |
Average Volume (1 week) | 0 |
Average Volume (1 Month) | 0 |
52 Week Change | - |
52 Week High | - |
52 Week Low | - |
Spread (Intraday) | 0.3 (24%) |
Company Name | Barinthus Biotherapeutics PLC |
Address |
unit 6-10, zeus building oxfordshire OX11 0DF |
Website | https://www.barinthusbio.com/ |
Industry | offices-holdng companies,nec (6719) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions